静止 状態 と 心血管 疾患 と 死亡 率: アメリカ 心臓 協会 の 科学 的 助言
Circulation
|August 17, 2016
まとめ
過剰な静止生活は 心血管疾患と死亡率のリスクを高めます 公共衛生のガイドラインは 座っている時間を最小限に抑えるよう勧めていますが 仕組みや効果的な介入を理解するには もっと研究が必要です
科学分野:
- 心血管の健康
- 公衆衛生の流行病学
背景:
- 増加する流行病学的な証拠は,座っている行動の増加と,すべての原因および心血管疾患による死亡率の増加を関連付けています.
- これらのリスクのために 座っている時間を 減らすことを勧告するガイドラインを 制定しています
- 長期にわたる静止行動の有害な影響に関する研究は進んでおり,詳細な生物学的メカニズムの解明に先行する疫学的な発見があります.
研究 の 目的:
- 座っている行動に関する現在の証拠を見直し,評価,流行,決定因子,健康関連をカバーする.
- 静止状態と心血管疾患との関連を 探求する.
- この分野における介入を要約し,将来の研究のための勧告を提供すること.
主な方法:
- 静止行動に関する疫学文献のレビュー
- 現在の評価方法と人口の流行データに関する分析
- 決定因子,心血管疾患関連,介入に関する研究の検討
主要な成果:
- 静止状態は一貫して心血管疾患の発生率と死亡率の増加と関連しています.
- 伝染病学的なデータは健康への悪影響を強く示唆しているが,その根底にある生物学的経路についてはさらなる調査が必要である.
- 現在の介入の効果は様々で,よりターゲット化された戦略の必要性を強調しています.
結論:
- 静止状態は 心血管の健康に重大な危険をもたらします
- 仕組みの理解を深め,根拠に基づいた公衆衛生のガイドラインと介入策を策定するために,さらなる研究が不可欠です.
- 静止状態の時間を最小限に抑えることは 心血管疾患の改善のための重要な公衆衛生目標です
関連する概念動画
01:17Ischemic Heart Disease: Overview
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
01:30Coronary Artery Disease I: Introduction
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
01:26Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
01:26Coronary Artery Disease IV: Preventive Measures
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
01:28Hypertension IV: Drug Therapy and Lifestyle Modifications
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...